TKIs such as Gleevec in CML and Tarceva in Lung Cancer benefit millions of patients world-wide every year, but recent research shows that the resistance to TKIs in patients of East Asian decent is higher than in Europe or North America due to unique mechanisms of resistance that are highly prevalent in these populations. DelMar is developing new data demonstrating that VAL-083 will benefit these patients, which will allow physicians to prescribe the medication in a new way and rapidly expand the current market.

Secondly, we are looking to leverage activity against resistant tumors to expand beyond China. Based on success in China, we will seek regulatory approval in additional Asia Pacific countries where similar mechanisms of TKI resistance are prevalent.

Importantly, we are seeking additional collaborations with a marketing partner with an existing oncology sales infrastructure in China in order to most efficiently and rapidly use DelMar's new data to tap the China market opportunity. Ideally, this partner will also have regulatory expertise and marketing infrastructure throughout the Asia Pacific region too.

What are the future goals of the company?
Overall, our goal is to benefit patients and build shareholder value by rapidly developing and commercializing proven chemotherapies in new cancer indications. We will invest in therapies where the mechanism of action suggests the potential to benefit patients who are failing other treatments. We have initially focused on VAL-083, but over time, we will seek to expand our pipeline in order to include new drug candidates that meet these criteria.